Related Experiment Video

Updated: Jun 8, 2026

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay
11:14

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay

Published on: November 10, 2013

Antimicrobial and non-antimicrobial tetracyclines in human cancer trials

Christopher Richards1, Liron Pantanowitz, Bruce J Dezube

  • 1Department of Hematology and Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States.

Pharmacological Research
|October 19, 2010
PubMed

Insights

Tetracyclines inhibit collagenases, potentially slowing cancer. While many trials disappointed, some tetracycline derivatives show anti-cancer effects, especially in specific tumor types reliant on these enzymes.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Tetracyclines possess non-antimicrobial properties that inhibit mammalian collagenases and matrix metalloproteinases.
  • These enzymes are implicated in cancer pathogenesis, including tumor growth, invasion, and metastasis.
  • FDA-approved tetracycline derivatives are used for inflammatory conditions, suggesting therapeutic potential.

Purpose of the Study:

  • To review the efficacy of tetracyclines as chemotherapeutics in human cancer clinical trials.
  • To assess the anti-cancer effects and tolerability of tetracyclines.
  • To identify specific cancer subtypes where tetracyclines might be effective.

Main Methods:

  • Review of clinical trials investigating tetracyclines for cancer treatment.
  • Analysis of data on drug tolerability and anti-proliferative effects.
  • Evaluation of outcomes in specific cancer types, including Kaposi Sarcoma.

Main Results:

  • Most clinical trials yielded disappointing results regarding overall efficacy.
  • Tetracyclines were generally well-tolerated in patients.
  • Significant anti-proliferative effects were observed in certain cancer types, notably with COL-3 (CMT-3) in Kaposi Sarcoma.

Conclusions:

  • Tetracyclines show limited but promising anti-cancer activity, particularly in specific neoplasms.
  • Further research should focus on cancer subtypes heavily reliant on collagenases and matrix metalloproteinases.
  • Targeted application of tetracyclines may improve outcomes in selected oncological indications.

More Related Videos

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Related Concept Videos

Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...